ASCO white blood cell growth factor guidelines
Executive Summary
Updated guidelines from the American Society of Clinical Oncology lower the recommended risk level for when cancer patients at risk of febrile neutropenia should receive hematopoietic colony stimulating factors. The new guidelines recommend CSF use when the risk of febrile neutropenia is 20% or greater. It was previously 40%. Amgen's Neulasta (pegfilgrastim) and Neupogen (filgrastim) as well as Schering AG's Leukine (sargramostim) are used in cancer treatment-induced febrile neutropenia. Amgen does not expect the guidelines to affect reimbursement for Neulasta since payers already reimburse based on a recent labeling update allowing treatment at the 17% febrile neutropenia risk level...
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.